Format

Send to

Choose Destination
Cytokine. 2016 Feb;78:22-6. doi: 10.1016/j.cyto.2015.11.020. Epub 2015 Nov 28.

Therapeutic potential of low-dose IL-2 in a chronic GVHD patient by in vivo expansion of regulatory T cells.

Author information

1
The Institute for Translational Research and Molecular Imaging, The Catholic University of Korea College of Medicine, Seoul, Republic of Korea; Laboratory of Immune Regulation, Convergent Research Consortium for Immunologic Disease, Seoul, Republic of Korea.
2
The Institute for Translational Research and Molecular Imaging, The Catholic University of Korea College of Medicine, Seoul, Republic of Korea; Laboratory of Immune Regulation, Convergent Research Consortium for Immunologic Disease, Seoul, Republic of Korea; The Catholic Blood and Marrow Transplantation Center, Seoul St. Mary's Hospital, The Catholic University of Korea College of Medicine, Seoul, Republic of Korea.
3
The Institute for Translational Research and Molecular Imaging, The Catholic University of Korea College of Medicine, Seoul, Republic of Korea; Laboratory of Immune Regulation, Convergent Research Consortium for Immunologic Disease, Seoul, Republic of Korea; The Catholic Blood and Marrow Transplantation Center, Seoul St. Mary's Hospital, The Catholic University of Korea College of Medicine, Seoul, Republic of Korea. Electronic address: chosg@catholic.ac.kr.

Abstract

Chronic graft-versus-host disease (cGVHD) is a common complication following allogeneic hematopoietic stem cell transplantation (HSCT), which is characterized by autoimmune like inflammatory responses and reduced levels of regulatory T cells (Tregs). Recently, the use of low-dose IL-2 has been reported to selectively increase Tregs and therefore facilitate immune regulation and promote clinical improvements in cGVHD patients. In this report, we describe the case of a cGVHD patient who was treated with daily low-dose IL-2 therapy. Our observations demonstrate that low-dose IL-2 could induce significant expansion of Tregs in vivo leading to improved Treg/Th17 ratios. The patient showed moderate clinical benefits suggesting that multiple factors may be involved in the immunological responses. Therefore, while the therapeutic potential of low-dose IL-2 is promising, strategic approaches may be needed to induce a clinically significant and sustained Treg effect.

KEYWORDS:

Allogeneic hematopoietic stem cell transplantation; Chronic graft-versus-host disease; Immunotherapy; Interleukin-2; Regulatory T cell

PMID:
26624506
DOI:
10.1016/j.cyto.2015.11.020
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center